|
1
|
Truong PT, Olivotto IA, Whelan TJ and
Levine M: Clinical practice guidelines for the care and treatment
of breast cancer: 16. Locoregional post-mastectomy radiotherapy.
CMAJ. 170:1263–1273. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bartelink H, Horiot JC, Poortmans P, et
al: Recurrence rates after treatment of breast cancer with standard
radiotherapy with or without additional radiation. N Engl J Med.
345:1378–1387. 2001. View Article : Google Scholar
|
|
3
|
Liu Q, Guntuku S, Cui XS, et al: Chk1 is
an essential kinase that is regulated by Atr and required for the
G(2)/M DNA damage checkpoint. Genes Dev. 14:1448–1459.
2000.PubMed/NCBI
|
|
4
|
Kastan MB and Bartek J: Cell-cycle
checkpoints and cancer. Nature. 432:316–323. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gao Q, Huang X, Tang D, et al: Influence
of chk1 and plk1 silencing on radiation- or cisplatin-induced
cytotoxicity in human malignant cells. Apoptosis. 11:1789–1800.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bartek J and Lukas J: Chk1 and Chk2
kinases in checkpoint control and cancer. Cancer Cell. 3:421–429.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Koniaras K, Cuddihy AR, Christopoulos H,
Hogg A and O’Connell MJ: Inhibition of Chk1-dependent G2 DNA damage
checkpoint radiosensitizes p53 mutant human cells. Oncogene.
20:7453–7463. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Syljuasen RG, Sorensen CS, Hansen LT, et
al: Inhibition of human Chk1 causes increased initiation of DNA
replication, phosphorylation of ATR targets, and DNA breakage. Mol
Cell Biol. 25:3553–3562. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pan Y, Ren KH, He HW and Shao RG:
Knockdown of Chk1 sensitizes human colon carcinoma HCT116 cells in
a p53-dependent manner to lidamycin through abrogation of a G2/M
checkpoint and induction of apoptosis. Cancer Biol Ther.
8:1559–1566. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen Z, Xiao Z, Gu WZ, et al: Selective
Chk1 inhibitors differentially sensitize p53-deficient cancer cells
to cancer therapeutics. Int J Cancer. 119:2784–2794. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zabludoff SD, Deng C, Grondine MR, et al:
AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint
abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther.
7:2955–2966. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mitchell JB, Choudhuri R, Fabre K, et al:
In vitro and in vivo radiation sensitization of human tumor cells
by a novel checkpoint kinase inhibitor, AZD7762. Clin Cancer Res.
16:2076–2084. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bucher N and Britten CD: G2 checkpoint
abrogation and checkpoint kinase-1 targeting in the treatment of
cancer. Br J Cancer. 98:523–528. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Morgan MA, Parsels LA, Zhao L, et al:
Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762
involves abrogation of the G2 checkpoint and inhibition of
homologous recombinational DNA repair. Cancer Res. 70:4972–4981.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Maity A, McKenna WG and Muschel RJ: The
molecular basis for cell cycle delays following ionizing radiation:
a review. Radiother Oncol. 31:1–13. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Held KD: Radiation-induced apoptosis and
its relationship to loss of clonogenic survival. Apoptosis.
2:265–282. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Vakifahmetoglu H, Olsson M and Zhivotovsky
B: Death through a tragedy: mitotic catastrophe. Cell Death Differ.
15:1153–1162. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Brown JM and Attardi LD: The role of
apoptosis in cancer development and treatment response. Nat Rev
Cancer. 5:231–237. 2005.PubMed/NCBI
|
|
19
|
Aris SM and Pommier Y: Potentiation of the
novel topoisomerase I inhibitor indenoisoquinoline LMP-400 by the
cell checkpoint and Chk1-Chk2 inhibitor AZD7762. Cancer Res.
72:979–989. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Vance S, Liu E, Zhao L, et al: Selective
radiosensitization of p53 mutant pancreatic cancer cells by
combined inhibition of Chk1 and PARP1. Cell Cycle. 10:4321–4329.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bartucci M, Svensson S, Romania P, et al:
Therapeutic targeting of Chk1 in NSCLC stem cells during
chemotherapy. Cell Death Differ. 19:368–378. 2011.PubMed/NCBI
|
|
22
|
Yang H, Yoon SJ, Jin J, et al: Inhibition
of checkpoint kinase 1 sensitizes lung cancer brain metastases to
radiotherapy. Biochem Biophys Res Commun. 406:53–58. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wilsker D, Chung JH and Bunz F: Chk1
suppresses bypass of mitosis and tetraploidization in p53-deficient
cancer cells. Cell Cycle. 11:1564–1572. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Origanti S, Cai SR, Munir AZ, White LS and
Piwnica-Worms H: Synthetic lethality of Chk1 inhibition combined
with p53 and/or p21 loss during a DNA damage response in normal and
tumor cells. Oncogene. Mar 19–2012.(E-pub ahead of print).
|
|
25
|
Tse AN, Sheikh TN, Alan H, Chou TC and
Schwartz GK: 90-kDa heat shock protein inhibition abrogates the
topoisomerase I poison-induced G2/M checkpoint in p53-null tumor
cells by depleting Chk1 and Wee1. Mol Pharmacol. 75:124–133. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jia XZ, Yang SY, Zhou J, et al: Inhibition
of CHK1 kinase by Go6976 converts 8-chloro-adenosine-induced G2/M
arrest into S arrest in human myelocytic leukemia K562 cells.
Biochem Pharmacol. 77:770–780. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Eriksson D and Stigbrand T:
Radiation-induced cell death mechanisms. Tumour Biol. 31:363–372.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Roninson IB, Broude EV and Chang BD: If
not apoptosis, then what? Treatment-induced senescence and mitotic
catastrophe in tumor cells. Drug Resist Updat. 4:303–313. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kesari S, Advani SJ, Lawson JD, et al: DNA
damage response and repair: insights into strategies for radiation
sensitization of gliomas. Future Oncol. 7:1335–1346. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
McNeely S, Conti C, Sheikh T, et al: Chk1
inhibition after replicative stress activates a double strand break
response mediated by ATM and DNA-dependent protein kinase. Cell
Cycle. 9:995–1004. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
O’Connor MJ, Martin NM and Smith GC:
Targeted cancer therapies based on the inhibition of DNA strand
break repair. Oncogene. 26:7816–7824. 2007.PubMed/NCBI
|
|
32
|
Tao ZF and Lin NH: Chk1 inhibitors for
novel cancer treatment. Anticancer Agents Med Chem. 6:377–388.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ashwell S, Janetka JW and Zabludoff S:
Keeping checkpoint kinases in line: new selective inhibitors in
clinical trials. Expert Opin Investig Drugs. 17:1331–1340. 2008.
View Article : Google Scholar : PubMed/NCBI
|
